Pituitary Adenoma: A Pathologic Classification of Tumors
School of Medicine Students' Journal,
Vol. 3 No. 3 (2021),
Background and aim:
The classification of pituitary adenomas now includes an “atypical” variant, which can be defined as MIB-1 proliferative index greater than 3%, excessive p53 immunoreactivity, invasive growth pattern, and the increased mitotic activity. Recent guidelines do not precisely define the cutoff points for elevated mitotic activity. Therefore, this study was designed to obtain reliable cut-off values for the mitotic index.
Materials and Methods:
In this study, the authors reviewed the records belonged to 300 patients including 250 patients with typical pituitary adenoma and 50 patients with atypical pituitary who were referred to Loghman Hakim Hospital between 2011 and 2017. Statistical analyses were performed using Fisher’s exact test and Mann Whitney. Also, Cut-off values were attained using ROC analysis.
In APAs group, 47.8% and 52.2% of the tumors were microadenomas and macroadenomas, respectively. 91.3% of the patients with APAs had Ki-67 labeling index more than 3%, and the presence of p53 protein was observed in all the patients with APAs. The mean number of mitosis in the TPAs and APAs groups was 0.62 and 2.5, respectively. In addition, our results showed significant threshold values for mitotic index (>2 mitosis within 10 high power fields). Also, there was no significant difference between the size of tumors and type of secretion hormones in the APA and TPA groups (P> 0.05).
We introduced a new cut-off for the mitosis index (greater than 2) that may help to more reliable diagnosis of atypical adenomas (APA). These findings will convince pathologists to adopt this clinicopathological classification, and those clinicians will consider it as helpful when choosing the appropriate therapeutic strategy.
- Mitosis; pituitary; atypical adenoma
How to Cite
2. Karavitaki N, editor Prevalence and incidence of pituitary adenomas. Annales d'endocrinologie; 2012: Elsevier.
3. Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. European journal of endocrinology. 2014;170(4):R121-R32.
4. DeLellis RA. Pathology and genetics of tumours of endocrine organs: IARC; 2004.
5. Hadzhiyanev A, Ivanova R, Nachev E, Elenkova A, Yaneva M, Zaharieva S, et al. Evaluation of prognostic utility of MIB-1 and p53 expression in pituitary adenomas: correlations with clinical behaviour and follow-up results. Biotechnology & Biotechnological Equipment. 2014;28(3):502-7.
6. Landolt AM, Shibata T, Kleihues P. Growth rate of human pituitary adenomas. Journal of neurosurgery. 1987;67(6):803-6.
7. Gejman R, Swearingen B, Hedley-Whyte ET. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Human pathology. 2008;39(5):758-66.
8. Thapar K, Yamada Y, Scheithauer B, Kovacs K, Yamada S, Stefaneanu L. Assessment of mitotic activity in pituitary adenomas and carcinomas. Endocrine pathology. 1996;7(3):215-21.
9. Rutkowski MJ, Alward RM, Chen R, Wagner J, Jahangiri A, Southwell DG, et al. Atypical pituitary adenoma: a clinicopathologic case series. Journal of Neurosurgery: Spine. 2017:1-8.
10. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws Jr ER. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. Journal of neurosurgery. 2011;114(2):336-44.
11. Takibi P. Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas. Turkish neurosurgery. 2013;23(2):226-31.
12. De Caro MDB, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM, et al. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurgical review. 2017;40(1):105-14.
13. Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F, et al. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology. 2015;101(2):143-50.
14. Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Lüdecke DK, Hölsken A, et al. Histological criteria for atypical pituitary adenomas–data from the German pituitary adenoma registry suggests modifications. Acta neuropathologica communications. 2015;3(1):50.
15. Saeger W, Honegger J, Theodoropoulou M, Knappe U, Schöfl C, Petersenn S, et al. Clinical impact of the current WHO classification of pituitary adenomas. Endocrine pathology. 2016;27(2):104-14.
16. Tortosa F, Webb S. Atypical pituitary adenomas: 10 years of experience in a reference centre in Portugal. Neurología (English Edition). 2016;31(2):97-105.
- Abstract Viewed: 14 times